News

ALLG reports a record number of its clinical trial results being readout at the upcoming ASH Conference. The world’s largest conference on blood, the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, is where ALLG’s leading members will present the readout of new trial results. This includes four podium presentations and eight poster presentations.

Presentation of clinical trial research results to this prestigious international conference, ASH 2024, further solidifies ALLG’s global reputation as Global Leaders with Global Impact… impacting the way blood cancer is treated worldwide.

ALLG has had 5 decades of impact through our clinical trial program and research, with our members focusing on evaluating the effectiveness of new treatments and improvements in survival and quality of life. Conducting research and sharing clinical trial results at ASH 2024 helps advance blood cancer treatments for patients.

We congratulate all 12 ALLG members on being selected to present the readout of their ALLG clinical trial results at ASH 2024

The American Society of Hematology (ASH)

The American Society of Hematology (ASH) is the world’s largest professional haematology society, with a global membership of more than 18,000 haematologists from approximately 100 countries who work together with one aim – to conquer blood disease.

ASH 2024 is the world’s largest blood conference. It supports haematologists in fostering high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders.

 

 

ALLG Members Presenting ASH

The 66th ASH Annual Meeting and Exposition will take place December 7-10, 2024, in San Diego, California, and the program will include a remarkable number of ALLG members presenting a record number of trial results on the world stage –  twelve in total!

ALLG CEO Delaine Smith said, “ALLG’s clinical trials have shifted the dial, added to global knowledge of Better treatments…Better lives by changing the way blood cancer is treated around the world. ALLG’s trials incorporate new therapies and build on previous research, allowing our doctors to deliver impactful trials that make a difference in the lives of blood cancer patients. Our members are extremely deserving, and it’s an incredible achievement to have so many of them present the results of ALLG’s impactful clinical trials at ASH 2024”.

CEO Delaine Smith

 

ALLG SAC Chair Professor Judith Trotman said, “Having a record number of ALLG member’s clinical trials being accepted to ASH 2024 is a testament to the importance of clinical trial research. Successful trials start with well-planned studies and building strong relationships with International Cancer Cooperative Trial Groups that share our vision. The success of ALLG trials is due to their design and being well-led, well-operated, and supported by our colleagues and partners. What a privilege to have so many of our members being recognised and presenting the readout of trial results at ASH 2024”.

SAC Chair Judith Trotman

Congratulations to ALLG members Dr Chyn Chua, Dr Sun Loo, A/Prof David Yeung and A/Prof Peter Mollee on being accepted to deliver the trial results of AMLM25 INTERVENE, AMLM26 INTERCEPT, CML13 ASCEND and MM24 ISAYMP as podium presentations.

Congratulations to ALLG members A/Prof Shaun Fleming, Dr Katharine Lewis, A/Prof Nada Hamad, Dr Nisha Thiagarajah, Prof Steven Lane, A/Prof Anoop Enjeti, Dr Sueh Li-Lim and A/Prof Gareth Gregory on being accepted to deliver the trial results of ALL09 SUBLIME, NHL35 PACIFIC, BM13 CTTC, NBCR, AMLM27 IMPRESS, MDS05 MYDAST, MM22 FRAIL-M, and NHL32 PCNSL as poster presentations.

ALLG supports and congratulates our twelve members for their conduct of excellent trials, their outstanding trial results that will make a difference in patients’ lives and for being selected to present this knowledge on the world stage.

 

 

About ALLG’s Blood Cancer Research

ALLG is the only not-for-profit Australasian clinical blood cancer group. Our mission is to create Better treatments…Better lives for patients with blood cancer.

ALLG’s 1,400 + researcher members conduct clinical trials across all blood cancers, including Acute and Chronic Leukaemia’s, Non-Hodgkin and Hodgkin Lymphomas, Multiple Myeloma, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPNs).

ALLG’s clinical trials and research have driven progress in blood cancer treatments and have improved survival rates for patients for over 50 years. As we remain steadfast in our 51st year we will continue to lead a strong collaborative clinical research program across all blood cancers to accelerate science, evidence and effective outcomes for patients.

Help support our research, as we aim for a cure.